<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02004821</url>
  </required_header>
  <id_info>
    <org_study_id>12.17.NIHS</org_study_id>
    <nct_id>NCT02004821</nct_id>
  </id_info>
  <brief_title>Clinical Trial in Constitutional Thinness</brief_title>
  <official_title>Génomique de la résistance à la Prise de Poids Dans la Maigreur Constitutionnelle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the molecular differences between a group of&#xD;
      Constitutionally Thin (CT) subjects and a group of controls.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Molecular differences (evaluated in plasma, fat and muscle biopsies, urines) between a group of CT subjects and a control group before, during and after 14 days of overnutrition</measure>
    <time_frame>6 weeks</time_frame>
    <description>Molecular analyses of plasma, fat and muscle biopsies and urine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic, anthropometric, histological, and microbiome differences between a group of CT subjects and a control group before, during, and after 14 days of overnutrition</measure>
    <time_frame>6 weeks</time_frame>
    <description>Metabolic differences (eg: lipids, amino-acids… in plasma and urine)&#xD;
Anthropometric differences (eg: weight, BMI, waist/ hip ratio)&#xD;
Histological (eg: muscle and fat tissue biopsies)&#xD;
Inflammation and metabolism specific marker differences&#xD;
Energy metabolism differences (eg: RER, RQ, Cox, Lox…)&#xD;
Bone quality differences (eg: bone mineral density)&#xD;
Microbiome differences</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Individuals With Constitutional Thinness</condition>
  <arm_group>
    <arm_group_label>Renutryl® Booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat). One bottle per day during 14 days.</intervention_name>
    <arm_group_label>Renutryl® Booster</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion criteria specific to subjects with constitutional thinness&#xD;
&#xD;
          -  Women: BMI less or equal to 17.5&#xD;
&#xD;
          -  Men: BMI less or equal to 18.5&#xD;
&#xD;
          -  Stable weight for at least 3 months&#xD;
&#xD;
        Inclusion criteria specific to subjects with normal weight&#xD;
&#xD;
          -  Men and women: BMI above or equal to 20 but not more than 25&#xD;
&#xD;
          -  Stable weight for at least 3 months&#xD;
&#xD;
          -  No previous family history of first or second-degree obesity&#xD;
&#xD;
        Inclusion criteria common to both groups&#xD;
&#xD;
          -  Age: between 18 and 35 at the inclusion visit&#xD;
&#xD;
          -  Normal blood sugar, liver function, lipid and coagulation profiles&#xD;
&#xD;
          -  Signed consent form to participate in the study&#xD;
&#xD;
          -  Signed consent form for genetic analysis&#xD;
&#xD;
          -  Acceptance of a moderate weight gain of 2 kg (less than 10% of body weight)&#xD;
&#xD;
          -  Beneficiary or member of a social security system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults with a legal guardian, or subjects unable to act freely due to a decision by a&#xD;
             legal or administrative authority,&#xD;
&#xD;
          -  Pregnancy in the case of women&#xD;
&#xD;
          -  Women without contraception&#xD;
&#xD;
          -  Vegetarian subjects or those with lactose intolerance&#xD;
&#xD;
          -  Subjects with an eating disorder (DSM IV)&#xD;
&#xD;
          -  Significant alcohol consumption equivalent to more than 10 glasses of wine per week&#xD;
&#xD;
          -  Severe progressive disorder (diabetes, for example)&#xD;
&#xD;
          -  Subjects who undertake intensive physical activity (more than 3 sessions of physical&#xD;
             activity per week)&#xD;
&#xD;
          -  Significant tobacco consumption equivalent to more than 10 cigarettes per day&#xD;
&#xD;
          -  Depression or psychiatric condition (treated with antidepressant or psychotropic&#xD;
             medication), depression questionnaire/score&#xD;
&#xD;
          -  Medical or surgical history considered by the investigator to be incompatible with&#xD;
             this study (stomach or intestinal surgery, for example)&#xD;
&#xD;
          -  Subjects receiving treatment that may interfere with the parameters measured:&#xD;
             antihypertensives (blockers, centrally acting antihypertensives), anti-hyperlipidemic&#xD;
             agents or corticosteroids for more than 8 days&#xD;
&#xD;
          -  Inclusion in a different clinical study within the previous 12 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Estour, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint-Étienne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Saint-Étienne</name>
      <address>
        <city>St-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>November 15, 2013</study_first_submitted>
  <study_first_submitted_qc>December 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thinness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

